Ifosfamide and Doxorubicin in the Treatment of Advanced Leiomyosarcoma

Leiomyosarcomas (LMS) are rare tumors with poor prognosis due to the high rate of recurrent and metastatic disease. The combination of doxorubicin (Adriamycin) and ifosfamide (AIM) results in moderate response rates of 10 to 30%. The aim of this study was to assess the efficacy of the AIM regimen along with multimodality treatment including surgery and radiotherapy in patients with LMS.
Source: Current Problems in Cancer - Category: Cancer & Oncology Authors: Source Type: research